Evidence map›Paper›PMID 36937957›Full record

ArticleFrontiers in pediatrics2023

Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with

Abraham Ipe, Anne Angiolillo, David Jacobsohn, Jinjun Cheng, Miriam Bornhorst, Joyce Turner, Anant Vatsayan

Open access · goldFull text readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Frontiers in oncology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Abraham IpeSchool of Medicine and Health Sciences, George Washington University, Washington, DC, United States.
Anne AngiolilloSchool of Medicine and Health Sciences, George Washington University, Washington, DC, United States.
David JacobsohnSchool of Medicine and Health Sciences, George Washington University, Washington, DC, United States.
Jinjun ChengSchool of Medicine and Health Sciences, George Washington University, Washington, DC, United States.
Miriam BornhorstSchool of Medicine and Health Sciences, George Washington University, Washington, DC, United States.
Joyce TurnerSchool of Medicine and Health Sciences, George Washington University, Washington, DC, United States.
Anant VatsayanSchool of Medicine and Health Sciences, George Washington University, Washington, DC, United States.
George Washington University · USChildren's National · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Germline Checkpoint Kinase 2 gene ( Case Presentation: We describe a case of a pediatric patient with a heterozygous pathogenic germline Conclusion: As conventional chemotherapy and radiation can potentially increase the risk of DNA damage and development of secondary malignancies, CD19 CAR-T therapy (tisagenlecleucel) can be used as a substitute for intensive re-induction chemotherapy and HCT in patients with a germline

Indexed as

B-ALLCAR-TCHEK2 mutationMDStisagenlecleucel

Identifiers

PMID36937957
PMCPMC10014590
OpenAlexW4322744803

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read12
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.